CoChat

Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics

Victor Fang, Yu Ming, Mackeen, Dhanya, Egan, James F. X., Zelop, Carolyn M. · 2009 · The Journal of Maternal-Fetal & Neonatal Medicine

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To compare maternal and neonatal outcomes of pregestational and gestational diabetics treated with insulin glargine versus Neutral Protamine Hagedorn (NPH) insulin. METHODS: A retrospective cohort study examining outcomes from pregestational and gestational diabetics treated with either insulin regimen. Comparisons were made using the t-test for continuous data and the Chi-square or Fisher's exact test for categorical data. RESULTS: Fifty-two pregnant women treated with insulin glargine were compared with 60 pregnant women treated with NPH. No significant differences in rates of maternal complications were noted. No significant differences in neonatal outcomes for gestational diabetics were noted. Among pregestational diabetics treated with insulin glargine, significantly fewer macrosomic infants (relative risk [RR], 0.38; 95% confidence intervals (CI), 0.17-0.87; p = 0.04) and lower rates of neonatal hyperbilirubinemia (RR, 0.27; 95% CI, 0.07-0.98; p = 0.05) were noted when compared with those treated with NPH. There were no cases of neonatal hypoglycemia in pregestational diabetics treated with glargine; however, 25% of infants born to mothers treated with NPH experienced hypoglycemia (p = 0.01). No fetal anomalies or deaths were observed in either treatment group. CONCLUSION: Insulin glargine use during pregnancy is not associated with increased maternal or neonatal morbidity compared with NPH insulin. Among pregestational diabetics, insulin glargine use was associated with lower rates of macrosomia, neonatal hypoglycemia and neonatal hyperbilirubinemia.

Overview

Integrity signals

Registry

Crossref · 10.1080/14767050802638170

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Cited by

See all 45

Metadata

Authors
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M.
Affiliations
  • University of Connecticut (US)
  • Saint Francis Hospital & Medical Center (US)
Corresponding author
Zelop, Carolyn M.
Venue
The Journal of Maternal-Fetal & Neonatal Medicine
Published
2009-01
Volume
22
Issue
3
Pages
249-253
ISSN
  • 1476-4954 (ISSN-L)
  • 1476-7058
OpenAlex
W2002981359
Cited by
45
References
16
Citations by year
2024: 1 · 2022: 1 · 2021: 2 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 7
FWCI
7.27
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Maternal-Fetal & Neonatal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin glargine, NPH insulin, gestational diabetes mellitus, pregestational diabetes, diabetes in pregnancy, neonatal outcomes, macrosomia, neonatal hypoglycemia, neonatal hyperbilirubinemia, maternal complications, insulin analogues
MeSH terms
Insulin Glargine, Adult, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Insulin, Isophane, Male, Pregnancy, Pregnancy in Diabetics, Pregnancy Outcome, Retrospective Studies, Cohort Studies, Diabetes, Gestational, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. https://app.cochat.ai/papers/10.1080/14767050802638170
The paper
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009). Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. The Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.1080/14767050802638170

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.